Literature DB >> 27348501

Evaluation of mortality and readmissions following hospitalization with heart failure.

Jason P Swindle1, Wing W Chan2, Katherine Waltman Johnson2, Laura Becker1, Cori Blauer-Peterson1, Aylin Altan1.   

Abstract

OBJECTIVE: To examine the association of patient/clinical characteristics with mortality and readmission following a heart failure (HF)-related hospitalization. RESEARCH DESIGN AND METHODS: Claims data, linked to laboratory, race/ethnicity, and mortality data, from a large US health plan were utilized to identify individuals with ≥1 inpatient claim with a diagnosis code for HF (1 January 2008-30 September 2012). Study variables were analyzed using descriptive and multivariable approaches to identify patient/clinical characteristics associated with post-discharge outcomes. MAIN OUTCOME MEASURES: Primary outcomes included post-discharge mortality and readmission.
RESULTS: A total of 126,214 individuals were identified with a HF-related hospitalization; 19.1% with data to calculate chronic kidney disease (CKD) stage. For the overall sample, mortality probability was 4.9% and 13.4% at 1 and 6 months post-discharge, respectively (4.5% and 12.4% for subset with calculated CKD stage), while readmission (all-cause) probability was 14.8% and 39.6% at 1 and 6 months post-discharge, respectively (18.4% and 44.5% for subset with calculated CKD stage). Within the subset with calculated CKD stage, mortality and readmission probabilities differed by CKD stage (p < 0.001), with decreased renal function corresponding with increased risk of mortality and readmission. After multivariable adjustment, increasing age was associated with increased risk of mortality, while advancing CKD stage, various index hospitalization variables (i.e., pre-admission emergency room visit, intensive care unit during hospitalization), and baseline all-cause hospitalization were associated with both increased risk of mortality and all-cause 1 month readmission.
CONCLUSIONS: Calculated CKD, various index hospitalization variables, and baseline all-cause hospitalization were associated with increased risk of mortality and all-cause 1 month readmission among patients hospitalized with HF. Risk of post-discharge readmission and mortality increased with worse renal function, suggesting that improved management of this subset may reduce the burden and cost of this disease. Key study limitations include those related to retrospective claims-based studies and that renal function data were available for a subset of study patients.

Entities:  

Keywords:  Heart failure; chronic kidney disease; hospitalization; mortality; readmission

Year:  2016        PMID: 27348501     DOI: 10.1080/03007995.2016.1205972

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

1.  Prognostic Impact of Chronic Kidney Disease in Patients with Heart Failure.

Authors:  Nektar Nikki Hakopian; Derenik Gharibian; Marlene M Nashed
Journal:  Perm J       Date:  2019-09-05

2.  Structural heart disease as the cause of syncope.

Authors:  R B Guimarães; V Essebag; M Furlanetto; J P G Yanez; M G Farina; D Garcia; E D Almeida; L Stephan; G G Lima; T L L Leiria
Journal:  Braz J Med Biol Res       Date:  2018-03-01       Impact factor: 2.590

3.  Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event.

Authors:  Michael M Givertz; Mei Yang; Gregory P Hess; Bin Zhao; Ashwin Rai; Javed Butler
Journal:  ESC Heart Fail       Date:  2021-03-10

4.  Remote Patient Management May Reduce All-Cause Mortality in Patients With Heart-Failure and Renal Impairment.

Authors:  Marcel G Naik; Klemens Budde; Kerstin Koehler; Eik Vettorazzi; Mareen Pigorsch; Otto Arkossy; Stefano Stuard; Wiebke Duettmann; Friedrich Koehler; Sebastian Winkler
Journal:  Front Med (Lausanne)       Date:  2022-07-11

5.  Perspective Review: Type 2 Diabetes and Readmission for Heart Failure.

Authors:  Merlin C Thomas
Journal:  Clin Med Insights Cardiol       Date:  2018-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.